NEW YORK ( TheStreet) -- CHANGE IN RATINGS
downgraded at Jefferies from Buy to Hold. See limited upside to the $12.75 takeover bid from TEL.
initiated at Citi with a Buy rating and $45 price target. Favorable overall view of Medicaid, and Amerigroup is our favorite name.
upgraded at Goldman from Neutral to Buy. $17 price target. Company should benefit from falling iron ore prices.
(ALL - Get Report)
rated new Perform at Oppenheimer. Agency network is the company's most valuable asset.
initiated at Credit Suisse with an Outperform rating and $17 price target. The company's gene shuffling platform technology and blue chip customers create long-term value.
initiated at Citi with a Buy rating and $27 price target. A significant portion of Centene's revenue was up for bid in first half of 2010, but the next six months look better.
upgraded at UBS. CRM was upgraded from Neutral to Buy. $111 price target. Estimates also boosted, given the opportunity for the Chatter product.
initiated at Citi with a Sell rating and $10 price target. Health care reform could decimate eHealth's business model.
upgraded at UBS from Neutral to Buy. $63 price target. Stock is already pricing in lower earnings, and the company has room to cut costs.
rated new Perform at Oppenheimer. Stock is largely pricing in the company's growth potential.
rated new Negative at Susquehanna. $6 price target. Company needs to raise significant capital, which will dilute current investors.
downgraded at Credit Suisse to Neutral from Outperform. We see heightened risk of LNC realizing impairments on either goodwill assets, DAC assets, or statutory reserves. Price target cut to $30.
downgraded at Morgan Stanley from Equal-weight to Underweight. Competition is heating up, and the company faces currency risks.
downgraded at Goldman to Neutral. Company was also removed from the Conviction Buy list, as the large land purchase will require higher operating costs.